<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oasis 4 clinical trial &#8211; Bitfinance</title>
	<atom:link href="https://bitfinance.news/en/etiqueta/oasis-4-clinical-trial/feed/" rel="self" type="application/rss+xml" />
	<link>https://bitfinance.news</link>
	<description>Fintech &#38; new economy info</description>
	<lastBuildDate>Fri, 13 Nov 2026 11:25:35 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bitfinance.news/wp-content/uploads/2025/01/favicon-64.png</url>
	<title>Oasis 4 clinical trial &#8211; Bitfinance</title>
	<link>https://bitfinance.news</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Spain approves Wegovy, the first oral treatment for obesity</title>
		<link>https://bitfinance.news/en/spain-approves-wegovy-the-first-oral-treatment-for-obesity/</link>
		
		<dc:creator><![CDATA[Marilin Pino]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 18:00:21 +0000</pubDate>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Other topics]]></category>
		<category><![CDATA[30 tablets]]></category>
		<category><![CDATA[adults with a BMI of 30 or higher]]></category>
		<category><![CDATA[Body Mass Index]]></category>
		<category><![CDATA[first oral medication for obesity]]></category>
		<category><![CDATA[GLP-1 receptor agonist]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[Oasis 4 clinical trial]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[spain]]></category>
		<category><![CDATA[tablet presentation]]></category>
		<category><![CDATA[Wegovy]]></category>
		<category><![CDATA[weight loss]]></category>
		<guid isPermaLink="false">https://bitfinance.news/?p=125415</guid>

					<description><![CDATA[<div style="margin-bottom:20px;"><img width="1100" height="733" src="https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="La empresa farmacéutica Novo Nordisk comercializará en España el producto Wegovy, el primer tratamiento oral bajo prescripción médica para pacientes con sobrepeso u obesidad" decoding="async" fetchpriority="high" srcset="https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash.jpg 1100w, https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash-300x200.jpg 300w, https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash-1024x682.jpg 1024w, https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash-768x512.jpg 768w" sizes="(max-width: 1100px) 100vw, 1100px" /></div><p>The pharmaceutical company Novo Nordisk will be responsible for marketing the oral presentation of Wegovy (semaglutide 25 mg) in Spain, the first treatment of its kind for weight loss and obesity management. Wegovy will be marketed in Spain without public funding, at a cost of €236.20 for a 30-tablet dose. “The medication, administered as daily [&#8230;]</p>
<p>La entrada <a rel="nofollow" href="https://bitfinance.news/en/spain-approves-wegovy-the-first-oral-treatment-for-obesity/">Spain approves Wegovy, the first oral treatment for obesity</a> apareció primero en <a rel="nofollow" href="https://bitfinance.news/en">Bitfinance</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="1100" height="733" src="https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="La empresa farmacéutica Novo Nordisk comercializará en España el producto Wegovy, el primer tratamiento oral bajo prescripción médica para pacientes con sobrepeso u obesidad" decoding="async" srcset="https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash.jpg 1100w, https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash-300x200.jpg 300w, https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash-1024x682.jpg 1024w, https://bitfinance.news/wp-content/uploads/2026/11/jorge-campos-WAgSCeCGB5Y-unsplash-768x512.jpg 768w" sizes="(max-width: 1100px) 100vw, 1100px" /></div><p class="MsoNormal" style="text-align: justify;"><span lang="EN-US">The pharmaceutical company <strong>Novo Nordisk</strong> will be responsible for <strong>marketing the oral presentation of Wegovy (semaglutide 25 mg) in Spain,</strong> the first treatment of its kind for <strong>weight loss and obesity management.</strong></span></p>
<p class="MsoNormal" style="text-align: justify;"><span lang="EN-US">Wegovy will be marketed in Spain without public funding, <strong>at a cost of €236.20 for a 30-tablet dose.</strong></span></p>
<p class="MsoNormal" style="text-align: justify;"><span lang="EN-US">“The medication, administered as <strong>daily tablets taken in the morning,</strong> works as a GLP-1 receptor agonist that increases the feeling of satiety in the body.”</span></p>
<p class="MsoNormal" style="text-align: justify;"><span lang="EN-US">It was approved for use in<strong> adults with a “Body Mass Index (BMI) of 30 or higher,</strong> or from a BMI of 27 in the presence of weight-related comorbidities, always as a complement to <strong>a low-calorie diet and physical activity.”</strong></span></p>
<p class="MsoNormal" style="text-align: justify;"><span lang="EN-US">The developing company presented<strong> data from the Oasis 4 clinical trial,</strong> which showed an average <strong>body weight reduction of 16.6 % at the end of 64 weeks of follow-up, </strong>“achieving a loss of more than 20 % in one-third of the patients evaluated in the study.”</span></p>
<p class="MsoNormal" style="text-align: justify;"><span lang="EN-US">M.Pino</span></p>
<p class="MsoNormal"><em><span lang="EN-US">Source: </span><a href="https://2001online.com/internacionales/espana-aprueba-el-primer-tratamiento-oral-contra-la-obesidad-202611818390" target="_blank" rel="noopener"><span lang="EN-US">2001online</span></a></em></p>
<p class="MsoNormal"><span lang="EN-US">(Reference image source: Jorge Campos on Unsplash)</span></p>
<p class="MsoNormal"><em><b><span lang="EN-US" style="color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Follow our news on Google!</span></b></em><em><span lang="EN-US" style="color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> For current, interesting, and accurate information, </span></em><a href="https://www.google.com/search?q=site:bitfinance.news&amp;tbm=nws&amp;tbs=sbd:1" target="_blank" rel="noopener"><b><i><span lang="EN-US" style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">click here</span></i></b></a><em><span lang="EN-US" style="color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> to see all the content on <b>Bitfinance.news</b>. You can also find us on </span></em><a href="https://twitter.com/BitFinance_News" target="_blank" rel="noopener"><b><i><span lang="EN-US">X/Twitter</span></i></b></a><em><span lang="EN-US" style="color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> and </span></em><a href="https://www.instagram.com/bitfinancenews/?hl=es" target="_blank" rel="noopener"><b><i><span lang="EN-US" style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Instagram</span></i></b></a></p>
<p>La entrada <a rel="nofollow" href="https://bitfinance.news/en/spain-approves-wegovy-the-first-oral-treatment-for-obesity/">Spain approves Wegovy, the first oral treatment for obesity</a> apareció primero en <a rel="nofollow" href="https://bitfinance.news/en">Bitfinance</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
